IRLANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
IRulya Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$34.45+2.42 (+7.56%)
Close on Oct 19, 2026
- Market cap
- $211.28M
- P/E (TTM)
- –
- Dividend yield
- –
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
9 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -53.4% | 3016.5% | |
| Return on assets | – | -49.0% | -80.7% | |
| Current ratio | – | 8.11 | 0.53 | |
| Diluted shares | – | 3M | 5M |
Where the cash went
Fiscal 2021 to 2025, five years combined
IRulya Therapeutics generated $198.59M from operations and spent $1.08M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$198.59M
Used
$1.08M
Capital expenditure$1.08M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$83.98M
- Cash generatingOperating cash flow above zero-$41.43M
- Return on assets improvedROA up on the prior year-33.8% → -73.4%
- Earnings backed by cashOperating cash flow above net income-$41.43M vs -$83.98M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose6.05 → 0.53
- No dilutionShare count did not rise4M → 5M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –